Pathios Therapeutics Appoints Sumeet Ambarkhane, M.D., as Chief Medical Officer [Yahoo! Finance]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Yahoo! Finance
Dr. Sumeet Ambarkhane Will Guide Development of First-in-class Oncology Program Based on Genetically Validated Protective Effects of GPR65 Antagonism OXFORD, England March 24, 2025 /PRNewswire/ -- Pathios Therapeutics Limited ("Pathios"), a biotech company focused on the development of first-in-class therapies for cancer, today announced the appointment of Sumeet Ambarkhane, M.D., as Chief Medical Officer (CMO). A physician by training, Dr. Ambarkhane possesses more than 20 years of experience across academia and the biopharmaceutical industry in areas spanning clinical care, early through late-stage drug development, regulatory and commercialization. In his new role with Pathios, he will guide the advancement of the company's novel therapeutic programs, including PTT-4256, its lead internally discovered, oral, highly potent, and selective small molecule inhibitor of GPR65, which is currently being evaluated in a first-in-human clinical trial in advanced solid cancers. Dr. Ambark
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Bristol-Myers Squibb: Recent Gains Impress, But Tricky Tests Lie Ahead [Seeking Alpha]Seeking Alpha
- FDA Approves Bristol-Myers Squibb's Breyanzi as First-Ever CAR T Therapy for Rare Marginal Zone Lymphoma [Yahoo! Finance]Yahoo! Finance
- BofA Upgrades Bristol-Myers Squibb (BMY) Stock to Buy from Neutral [Yahoo! Finance]Yahoo! Finance
- Bristol-Myers blood thinner Eliquis offered free to Medicaid as part of U.S. pricing deal [Seeking Alpha]Seeking Alpha
- Great week for Bristol-Myers Squibb Company (NYSE:BMY) institutional investors after losing 0.8% over the previous year [Yahoo! Finance]Yahoo! Finance
BMY
Earnings
- 10/31/25 - Beat
BMY
Sec Filings
- 11/18/25 - Form 8-K
- 11/12/25 - Form CERT
- 11/10/25 - Form 8-A12B
- BMY's page on the SEC website